secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0001104659-22-109389
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion reports $71.7M cash; progressing Phase 2 NASH and upcoming HCC trials
----------------------------------------------------------------------------

- Cash and equivalents of $71.7M as of June 30, 2022; 76.2M common shares outstanding.
- Rencofilstat Phase 2b ASCEND-NASH (biopsy) and Phase 2 ALTITUDE-NASH (liver function) trials underway.
- Upcoming Phase 2a HCC trial for rencofilstat in advanced hepatocellular carcinoma.
- AI-POWR platform used to identify responders and companion diagnostic panel.
- Rencofilstat shown safe/tolerated in >200 subjects; Phase 2a AMBITION study met primary endpoints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465922109389/0001104659-22-109389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465922109389/tm2228403d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-109389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer